Topical beta-blocker may offer new option for feline angiomatosis: full analysis

A new feline dermatology case report suggests that topical beta-blockade may offer a limb-sparing option for a rare vascular lesion that has historically pushed clinicians toward surgery. In Veterinary Dermatology, Accard, Bitar, and Sanchez reported a 5-year-old female cat with a purple, depressed lesion on a metatarsal pad that caused ulceration and pain and was diagnosed as cutaneous angiomatosis. The lesion was successfully treated with a topical beta-blocker, according to the report. (bibliodermavet.vetup.com)

That matters because cutaneous angiomatosis is uncommon in cats, and the published veterinary record is sparse. Earlier reports have described progressive, infiltrative vascular lesions affecting feline pads, sometimes with repeated bleeding and recurrence after local treatment. A 2009 JAVMA case described invasive cutaneous angiomatosis of a metacarpal pad managed with complete pad resection, while another feline report summarized in the dermatology literature described recurrence in the metatarsal region and ultimately treated the cat with amputation when resection was not successful. Laser photocoagulation has also been reported as a treatment approach in cats and dogs. (pubmed.ncbi.nlm.nih.gov)

The new case appears to shift that pattern by using a topical beta-blocker rather than a procedural intervention. While the source summary does not provide the full treatment protocol, it describes a slow progressive lesion on the metatarsal pad of a 5-year-old female cat that was painful and ulcerated, and identifies the lesion as a rare, non-neoplastic vascular proliferation. That distinction is clinically important, because angiomatosis can resemble neoplastic or more aggressive vascular disease on presentation and histopathology is needed to secure the diagnosis. Veterinary pathology references describe progressive angiomatosis as infiltrative and locally destructive despite its non-neoplastic classification. (bibliodermavet.vetup.com)

There is at least some biologic plausibility for the approach. In human dermatology, topical beta-blockers, especially timolol, have been used off-label for infantile hemangiomas and other vascular proliferations, and a 2021 review concluded they appear to be a safe and valid option in multiple cutaneous diseases, though the evidence base remains limited and largely non-randomized. Human case reports have also described successful use of topical timolol or propranolol in reactive angiomatoses and other vascular lesions, suggesting the mechanism may be relevant beyond classic hemangioma care. (pubmed.ncbi.nlm.nih.gov)

Direct expert reaction to this specific feline report was not readily available in open sources, but the broader veterinary and dermatology literature helps frame the significance. For clinicians, the appeal is obvious: a topical option for a painful footpad lesion could reduce the need for sedation, repeated surgery, or amputation in selected cases. That said, extrapolation should be cautious. Reviews of dermatologic timolol use note that most evidence comes from case reports and small series, and safety considerations still matter, particularly with beta-blockers’ potential systemic cardiovascular and respiratory effects if absorbed. Older feline research also shows that ophthalmic timolol can produce measurable physiologic effects in cats, underscoring the need for careful monitoring if topical formulations are used off-label on ulcerated or highly vascular skin. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this case expands the conversation around how rare vascular footpad lesions might be managed in cats. If topical beta-blockers can control pain, bleeding, and progression in some cases, they may offer a practical bridge between diagnosis and definitive treatment, or even a standalone option when surgery is not feasible or acceptable to the pet parent. It also reinforces the need to keep cutaneous angiomatosis on the differential list for chronic, purple, ulcerative pad lesions that may otherwise be mistaken for infection, trauma, or vascular neoplasia. (bibliodermavet.vetup.com)

What to watch: The next step is replication. Clinicians will want the full protocol details, including the specific beta-blocker used, concentration, frequency, duration, adverse-effect monitoring, and follow-up for recurrence. More case reports or small case series will be needed before this approach can be considered more than a promising off-label option for a rare condition. (pubmed.ncbi.nlm.nih.gov)